<SEC-DOCUMENT>0001437749-15-005795.txt : 20150323
<SEC-HEADER>0001437749-15-005795.hdr.sgml : 20150323
<ACCEPTANCE-DATETIME>20150323123936
ACCESSION NUMBER:		0001437749-15-005795
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150319
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150323
DATE AS OF CHANGE:		20150323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		15718296

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>govx20150323_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>govx20150323_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA2 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>
<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>WASHINGTON, D.C. 20549</B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 10%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align=center>

<P id=PARA5 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA7 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FORM 8-K</B></FONT></P>
<P id=PARA8 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA9 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CURRENT REPORT</B></FONT></P>
<P id=PARA10 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Pursuant to Section 13 or 15(d) of the</B></FONT></P>
<P id=PARA11 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Securities Exchange Act of 1934</B></FONT></P>
<P id=PARA12 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA13 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Date of report (Date of earliest event reported):&nbsp;&nbsp;</B><B>March 19, 2015</B></FONT></P>
<P id=PARA14 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 10%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align=center>

<P id=PARA16 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA17 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>GEOVAX LABS, INC.</B></FONT></P>
<P id=PARA18 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Exact name of registrant as specified in its charter)</B></FONT></P>
<P id=PARA19 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA20 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL32  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31.6%; VERTICAL-ALIGN: top">
<P id=PARA21 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 2.5%; VERTICAL-ALIGN: bottom">
<P id=PARA22 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.6%; VERTICAL-ALIGN: top">
<P id=PARA23 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>000-52091</B></FONT></P></TD>
<TD style="WIDTH: 2.5%; VERTICAL-ALIGN: bottom">
<P id=PARA24 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.6%; VERTICAL-ALIGN: top">
<P id=PARA25 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>87-0455038</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 31.6%; VERTICAL-ALIGN: top">
<P id=PARA26 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(State or other jurisdiction of</B></FONT></P>
<P id=PARA27 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>incorporation or organization)</B></FONT></P></TD>
<TD style="WIDTH: 2.5%; VERTICAL-ALIGN: bottom">
<P id=PARA28 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.6%; VERTICAL-ALIGN: top">
<P id=PARA29 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Commission File No.)</B></FONT></P></TD>
<TD style="WIDTH: 2.5%; VERTICAL-ALIGN: bottom">
<P id=PARA30 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.6%; VERTICAL-ALIGN: top">
<P id=PARA31 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(IRS Employee Identification No.)</B></FONT></P></TD></TR></TABLE>
<P id=PARA33 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA34 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA35 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>1900 Lake Park Drive, Suite 380</B></FONT></P>
<P id=PARA36 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Smyrna, Georgia 30080</B></FONT></P>
<P id=PARA37 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Address of principal executive offices) (Zip code)</B></FONT></P>
<P id=PARA38 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA39 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA40 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(678) 384-7220</B></FONT></P>
<P id=PARA41 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Registrant&#8217;s telephone number, including area code)</B></FONT></P>
<P id=PARA42 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA43 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA44 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.</FONT></P>
<P id=PARA45 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA46 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P id=PARA47 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA48 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</FONT></P>
<P id=PARA49 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA50 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</FONT></P>
<P id=PARA51 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA52 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))</FONT></P>
<P id=PARA53 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P>
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="MARGIN-BOTTOM: 0px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA54 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</P>
<DIV id=PGBK56  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR56  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM56  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR56  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA56.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P>
<P id=PARA60 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#8220;Registrant&#8221;) from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant&#39;s management as well as estimates and assumptions made by the Registrant&#8217;s management.&nbsp;&nbsp;When used in the Filings the words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221; or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant&#8217;s management identify forward looking statements.&nbsp;&nbsp;Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant&#8217;s industry, operations and results of operations and any businesses that may be acquired by the Registrant.&nbsp;&nbsp;Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.&nbsp;&nbsp;Except as required by law, the Registrant does not undertake to update its forward looking statements.</FONT></P>
<P id=PARA61 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA62 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></P>
<P id=PARA63 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA64 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective March&nbsp;19, 2015 our Board of Directors appointed Randal D. Chase, Ph.D. to the Board of Directors. </FONT></P>
<P id=PARA65 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA66 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dr. Chase will participate in our existing non-employee director compensation plan. Accordingly, he has received a grant of options to purchase 26,400 shares on the date he was first appointed as a director and will receive a pro rata portion of the annual retainer for serving on the Board and compensation for Board meetings he attends. The options granted to Mr.&nbsp;Chase have a ten year term and vest in equal amounts over three years beginning on the first anniversary of his appointment. The exercise price is $0.15 per share. </FONT></P>
<P id=PARA67 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA68 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Mr. Chase has not been appointed to any committees, nor has the Board made any determination to place him on specific committees. If he is appointed to committees he will be eligible to receive a pro-rated portion of the applicable annual retainers and compensation for meetings he attends. There was no arrangement or understanding between Dr. Chase and any person pursuant to which he was selected as a director. Dr. Chase has not been a party to any transaction with us that we would be obligated to report pursuant to Item&nbsp;404(a) of Regulation&nbsp;S-K nor has any such transaction been proposed. </FONT></P>
<P id=PARA69 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA70 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 23, 2015 the Registrant issued a press release (attached hereto as Exhibit&nbsp;99.1) announcing the appointment of Dr. Chase to the Board of Directors</FONT></P>
<P id=PARA71 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA72 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp; </B><B>Financial Statements and Exhibits</B></FONT></P>
<P id=PARA73 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA113 style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Press Release dated March 23, 2015</FONT></P>
<P id=PARA77 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA78 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA79 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA80 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SIGNATURE</B></FONT></P>
<P id=PARA81 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA82 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P id=PARA83 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA84 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dated: March 23, 2015</FONT></P>
<P id=PARA85 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL111  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA86 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 38%; VERTICAL-ALIGN: top" colSpan=2>
<P id=PARA87 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GEOVAX LABS, INC.</FONT></P></TD>
<TD style="WIDTH: 12%; VERTICAL-ALIGN: top">
<P id=PARA88 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA89 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 38%; VERTICAL-ALIGN: top" colSpan=2>
<P id=PARA90 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 12%; VERTICAL-ALIGN: top">
<P id=PARA91 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA92 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 38%; VERTICAL-ALIGN: top" colSpan=2>
<P id=PARA93 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 12%; VERTICAL-ALIGN: top">
<P id=PARA94 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA95 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 3.1%; VERTICAL-ALIGN: top">
<P id=PARA96 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">By: </FONT></P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA97 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">/s/ Mark W. Reynolds&nbsp;</FONT></P></TD>
<TD style="WIDTH: 12%; VERTICAL-ALIGN: top">
<P id=PARA98 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA99 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 3.1%; VERTICAL-ALIGN: top">
<P id=PARA100 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: bottom">
<P id=PARA101 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Mark W. Reynolds</FONT></P></TD>
<TD style="WIDTH: 12%; VERTICAL-ALIGN: top">
<P id=PARA102 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA103 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 3.1%; VERTICAL-ALIGN: top">
<P id=PARA104 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top">
<P id=PARA105 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chief Financial Officer</FONT></P></TD>
<TD style="WIDTH: 12%; VERTICAL-ALIGN: top">
<P id=PARA106 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA107 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 3.1%; VERTICAL-ALIGN: top">
<P id=PARA108 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top">
<P id=PARA109 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 12%; VERTICAL-ALIGN: top">
<P id=PARA110 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR></TABLE>
<P id=PARA112 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA35 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit 99.1</B></FONT></P>
<P id=PARA36 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P><IMG src="img.jpg" width=199 height=53>
<P id=PARA1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<P id=PARA2 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>GeoVax Appoints </B><B>Industry Veteran</B></FONT></P>
<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>to its Board of Directors</B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>&nbsp;</I></FONT></P>
<P id=PARA5 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Randal D. Chase, Ph.D. Brings Extensive Vaccine Background to GeoVax</I></FONT></P>
<P id=PARA6 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA7 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA8 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ATLANTA, GA, March 2</B><B>3</B><B>, 2015 </B>&#8211; GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.</FONT></P>
<P id=PARA9 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA10 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dr. Chase, 65, currently serves as a business advisor and consultant to companies in the life science sector. From 2006 to 2011, he served as President and Chief Executive Officer of Immunovaccine, Inc., a clinical-stage biotechnology company developing vaccines against cancer and infectious diseases. Dr. Chase is also a former president of Shire Biologics, North American Vaccine, Pasteur Merieux Connaught, and Quadra Logic Technologies, Inc. Earlier in his career Dr. Chase worked at Bristol Myers and Glaxo Pharmaceuticals. Dr. Chase has also served as a member of the board of directors for several companies, and recently served as Chairman of the Board for Medicago, Inc. until its sale to Mitsubishi Tanabe Pharma Corporation in 2013. He currently serves as Chairman of the Board for Medimabs, Inc., a privately-held antibody company. Dr. Chase attended the Senior Executive Program of the London Business School in the UK, holds a Bachelor of Sciences degree in Biochemistry from Bishop&#8217;s University, and a Ph.D. in Biochemistry from the University of British Columbia. Dr. Chase completed a post doctoral fellowship at the McArdle Cancer Institute of the University of Wisconsin. </FONT></P>
<P id=PARA11 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA12 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">David Dodd, GeoVax&#8217;s Chairman of the Board, commented, &#8220;Dr. Chase brings a wealth of experience to GeoVax, and we are very pleased to have him join our board. His experience and knowledge of business development and management, and of the vaccine industry, is extraordinary. We expect to rely on his professional acumen and experience serving other vaccine companies as GeoVax accelerates its Ebola, Marburg and HIV vaccine programs and expands its product development portfolio.&#8221;</FONT></P>
<P id=PARA13 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA14 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>About GeoVax</B></FONT></P>
<P id=PARA15 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA16 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our novel vaccine platform. Our current development programs are focused on vaccines against Ebola and Marburg viruses, and vaccines against Human Immunodeficiency Virus (HIV). We believe our technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline as resources permit.</FONT></P>
<P id=PARA17 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA18 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our vaccine platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Producing non-infectious virus-like particles in the person being vaccinated circumvents the need to purify virus-like particles for inoculation. The production of virus-like particles in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear. </FONT></P>
<P id=PARA19 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25">###</P>
<P id=PARA37.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK37  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR37  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM37  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR37  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA37.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA20 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Clinical trials for GeoVax&#8217;s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax&#8217;s vaccines, in various doses and combinations, have been tested in close to 500 humans. </FONT></P>
<P id=PARA21 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA22 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For more information, go to www.geovax.com.</FONT></P>
<P id=PARA23 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA24 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Forward-Looking Statements</B></I></FONT></P>
<P id=PARA25 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>&nbsp;</B></I></FONT></P>
<P id=PARA26 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act</I><I>.</I><I> These statements are based on management&#39;s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax&#39;s vaccines will be safe for human use, GeoVax&#39;s vaccines will effectively prevent HIV</I><I> or Ebola infection </I><I>in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax&#39;s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax&#39;s filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax&#39;s Form 10-K</I><I>.</I></FONT></P>
<P id=PARA27 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>&nbsp;</I></FONT></P>
<P id=PARA28 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Contact: </B></FONT></P>
<P id=PARA29 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Adam S. Holdsworth</FONT></P>
<P id=PARA30 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PCG Advisory Group</FONT></P>
<P id=PARA31 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">646-862-4607</FONT></P>
<P id=PARA32 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">www.pcgadvisory.com</FONT></P>
<P id=PARA33 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA34 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img.jpg
<TEXT>
begin 644 img.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``U`,<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MOGK]J'_@JI\`_P!D"2>U\9_$714UF`'.C::QU'4LC^$PPAF0_P#73:/>O@KX
M]_\`!U?I-F\]M\+_`(5ZCJ6#B+4?$U^MG&??[/!YC'\9%->EA<HQF(UI4W;N
M]%^)QU\PP]+2<M?O/UZH)P*_G9\5_P#!=S]KW]J?Q#)HW@W4AID]TVU--\$^
M&?M-TN>@#NL\H^H(K4T;_@F3^WM^VJ4N?%USXYM;*<@-)XU\7R6J*#_TZJ[N
M![>4*]3_`%:E25\56C#YZ_H</]LJ;M0IRE_7S/W8\??M0?#7X5!_^$F^(/@G
MP\8^674=<MK9A^#N#7BWC#_@M7^RQX(E>.[^-/A.XD3JNG>=J&?IY$;BOSQ^
M%?\`P:>>)=0D6?QQ\6_#VF,W+Q:%HDEZ_P!/-F>/\]E?1'P]_P"#73X#>'8$
M/B'Q+\2?%$ZXW;M1@L86_P"`PPAA_P!]UF\)E%/XZ\I?X5;\RUB,PG\--+U?
M^1VGBG_@Y(_9<\/2,MMKOB_6MO0V/AJY`;Z&41BN%\1?\'3/P#TP'[#X3^*6
MH>A;3[.W!_[ZN<_I7MW@W_@@K^REX-A4?\*IL]6D7_EIJNJ7MX6^H>8K^E>I
M>$?^":/[/7@55_LSX*?#&`KT9_#EK,WYNC&LW5R>/PPG+U:7Y%<F8/>45Z)G
MP;JG_!V7\,87(L_A9XWN/3S=1L8L_E(U9S?\'8_A>8_Z-\$O$\WIG7[<9_*,
MU^G^B_LX_#SPV`-.\!^#+`+T%MHEM%C_`+Y05T-GX.TC3ABWTK3H`.@CMD7'
MY"I^N98ML.__``-E?5\:]ZR_\!1^4"?\'6NE/T^`GBLCU&O1'_VA4\7_``=:
M>'D_X^/@5XSB'<KK$#?SC6OUD2P@C&%AB'T04DFFV\P^:"%OJ@-3]=R[_H&_
M\G?^0_JV+_Y_?^2H_*W3_P#@Z]^&.X?VA\*OB!9^NR[L9,?G(M=9X?\`^#J'
M]G;4L"^T'XFZ<QZ_\2VTG`_[XN2?TK]%[_P%H>J*1<Z+I-P#U$MG&^?S%<UK
M?[+?PR\3`_VE\.O`FH;NOVG0+27/_?49H^M9:]Z#7I/_`#0_8XQ;54_^W?\`
M@GS7\`O^"^/[.?[1OQ(T+PCH.N>)X?$'B2\2PL+6\\/72>;*_0%U5D4#DEF8
M*H!)(`)K\V_`/COPM_P5%_X+'>*_BA\3];TNS^!7PZN1/YFNWBP:6+.*46NF
MVS&0^6!=7/[]D_C`D!R*^T?^"U7A7X-?L!?LA:KXM\&?#?P%X6^)_BMI/"_A
MW5-*T:VL[RR-W#)'>3QM&H(VVAG&X="Z^M<5_P`$E_\`@C7X#^,?_!+;3+?X
MIZ7JDC_$O5X_&'DV=_-82PP1120:>K%"-P$,DDP5LJ#<YQD"O6PKP>'P\L93
MYHJ?N*]F_P"\UMTV\S@KK$5JT</.S<?>?1>2>_\`PQ^DOPW^-_P_^(%E!!X1
M\7>#]:MXT6.&+2-4MKA$4#`51$Q``'0"NRK\P_'_`/P:N?!/5',_A/QK\1?"
MEWU5GGMK]$/MNB5__'ZXQ_\`@AA^U1^SP6?X.?M6:JUO%S'9:E=7]@CXZ*4$
MES"?Q3%>3]2P%3^'B+/^]%K\5<[_`*SBH_'2OZ-?EH?K?17Y$R_'W_@IQ^Q]
MM;Q+X%T7XOZ-;`@RVEC!?R.H[YLFBGS[M":Z+X3?\'0OAG2M=30_C-\)O&7P
M^U>/Y+A[+_2UC;N6MYEAG4?17/UHED6):YJ#C47]UI_AN"S2BG:I>#\U8_52
MBO&?V9O^"A/P8_;"@7_A7GQ#\/:]>E=S:;Y_V;48^,G=;2A91CUVX]Z]FKR*
ME*=.7+433\]#OA.,US0=T%%%%04?/'_!0?\`X*8_#?\`X)R_#^+4O&%W-J&O
MZHCG1O#M@5:_U1EX+`$XCB!P&E?"CH-S84_AA^VW_P`%NOCI^VG<WE@VO2>`
M/!LY9$T#PY.]OYL9[7%T,33$CJ,HA_N5X7^V%^TQK_[87[2WB[XA^([B>6[U
MZ_D-K!(Q(TZR5B+>U0?PK''@8[MN8\L37N/_``1C_P""=-M_P43_`&II=.\0
MM/'X"\&6J:KX@$+E)+\,Y6"S5QROFLKEF&"$C<`@D$?I."RC"Y=A_K.(5Y)7
M;WMY)?J?'8G,*^+J^QHZ)[>?J<%^PU_P3$^+?_!0#6V'@+P^L'A^*<QWWB75
M";;2K9LC</,P6FD&>4B5F'\6WK7ZZ_LE_P#!M#\&?@[!;:A\2;W4_BKKJ@-)
M!<,UAH\;8Z+;QMOD`/\`SUD8'^Z.E?H9X'\#Z-\,_"&G:!X>TNQT71-)@6VL
MK&R@6&WM8UX"HB@`"M6OF<PXEQ6(;5)\D?+?YO\`RL>UA,FH4E>:YGY[?<<Y
M\,?@]X3^"OAR/2/!_AG0?"^EQ`!;72K"*TBXX&5C4`GW/-?G9_P55_X+N7WP
M)^*4OP;^`^DP^+?B8+@:??:C]F:]@TRZ;@6EO;IS<W0)&X?<C/!#MN5?LC_@
MI!^T==?LE?L,_$SX@:?@:KH.C2#32>BWDS+!;MCOB65#CVKX+_X-DOV*M+A^
M%VN?'_Q'!_:OBWQ'J-UI>BW=V/,DL[:-MMS<*Q_Y:SSF0,_7;'C.';..74:4
M:,\?BES*+LEWEY^2-,74J.I'"T-&]6^R\CS#0/\`@G/_`,%&/VH;0>(?%?Q<
MU3P9+>#SX[#4?&%Q8R1AN<?9M/C,47^[P1W`J]_PY7_;NB!"_M%IC_L?=<&?
M_(5?L=XG\<Z+X)CA;6=8TO2%N"5B-[=QVXE(ZA=Y&<9'3UK(_P"%\^!O^AS\
M*?\`@WM__BZO^WL4_@A%+RB1_95!?%)W]3QW_@EK\.?C)\'OV6QX4^.6L/XA
M\9>']8N[6#5&O3>_;[`E'MW\]@'DP'9<R`.-F#TS7T=5&U\4:;?>'_[6AU"Q
MFTORFF^V).K6_EKG<_F`[=HP<G.!@U^9_P"T_P#\'._P\^''C^?PY\+?!.L?
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M[(48Y?X\_P#!T?X,T#QW<Z+\+/AIK_Q%M[=BJZG<79TZ*[`."\,(BEF:,]F=
M4^E=+^SG_P`%T?@M_P`%*-,U?X,?$SPY?_#B_P#'EI-H`AU"Z2[TZ_>=#&85
MN-J&*8EOD$D:@M@!BV`?6P>6X_"3CBI4GRK=:;==-_P.#$8S"UXN@IZO;UZ:
MGUQ_P34_:UB_;;_8J\#?$`R1MJU]9"TUN-"/W&HP'RKD8'0%U+@?W76O=J_'
M#_@WT^*&L?L=?MI_%K]E?QG<%;C[;/>:7O)"R7MH`DQ0>EQ:>3./:$^M?J!^
MV=^TII_[('[+/CCXD:EL>+PMI<MS!"W_`"]7)^2WA_[:3-&G_`JX\SP+I8QT
M:6JE9Q\T]O\`(Z<%BN?#^TJ;K?U6Y^2'_!5K7+S_`(*F?\%F_`O[/^B7$LOA
MCP5<+I.H/"<K$[!;G59_K'!&D(]'C([U^V>@Z%9^%]#L],T^WBL[#3H$M;:"
M)<)!$BA411V`4`#Z5^'O_!$SQSX/_9%^&GQ0_:]^-^L/'/XBU&;P[H3"/S[_
M`%J[=_M5^UM%U=Y)=B9R`HAEW,%R:]&UO_@ZGU*_UB>\\.?`*_O?"UI(5ENK
MK7'$P4'JYBMGBB..Q=L>M>SF.6XFNXX7"QO"DK7T2<GJ]SSL'C*--2KUW:4W
M?Y=-C]AZ*_)75_\`@Z;T"77/!L^B_#B:]TC695M]>L[G43!J6B-YB*7B(C:"
MYC97W(0Z-F-E94RI/T;_`,%1O^"D_P`6O^";8L/$B?"?P_XY^&^HW*VO]L6^
MN36EQITS?=BN8C`ZIOY"2!BI;Y2%)4-XTLEQ<9QI3C9RO:[6MOG_`,/T/168
MX=Q<XNZ6^C/MVN.^,?[/?@7]H;P\VE>.O!_ASQ;8,I00ZKI\5T$!_NEP2I]U
M(-8_[)/[57A/]M#X`Z#\1/!MW]HTC6X<O"Y'GZ=<+Q+;3*/NRQME2._!&5()
M^,+;_@N-XC_:"_;SN?@K\`_ACI7C^TLIWM[CQ-J&NO9V,:0D+<W9\N"3%M&Q
MV*V296P%'S+G##X+$RG)4U9PU>MK?-FE7$T8QBYNZEMUN87[5G_!LC\+?B#+
M)K7PAU_6?A;XCA8S6UNTTE_I:R#E=H9A<0<_Q)*0.RU\_:3^WI^V'_P1:\7V
M'A[XYZ-<_$[X;2S"WM-3N+DW/FKT`M=3V[O,P.(;M=Q[;1\U?M=I/VL:9!]N
M^SF\\L>?Y`/E;\<[<\XSTS67\2/AMH'Q@\#:GX9\4Z/I^OZ!K,#6U[87T(F@
MN8SU#*?S!Z@@$8(KNHYW4:]EC%[6'GNO1[G-4RV*?M,.^27EM\T<%^QO^VS\
M/?V[OA+%XP^'NL?;[-7$%]93KY5]I,^,F&XBR2C8Z')5ARK,.:*_&OXO^&]<
M_P"#>+_@J%;:KX/EU#6/AKXTTJXN+;39968WMH0Z_9)C_'):W/E.DGWO+<9.
M6?)6]?A^K-JI@O>IR5UW]'Z&=+-817)B?=FM'_F<M_P6V_X))^)/V0/C%XA^
M)/A/2[C4_A+XHOI-2>:UC+GPO<3.7D@G4?=@+L3')]T!@C$$`MJ_\&WW[:?A
M[]FC]JS7O!OBJ\@TS2OBK:VMG8W\S!8H=1MWD,$3L>%$JS2*#TWA!_%7[]W]
MA!JMA-:W4,5S;7,;130RH'CE1AAE93P002"#US7YQ_MO_P#!MC\*?V@+F]US
MX9WK_"KQ%<EI'LX(/M.AW+GGFVR&@R?^>+!1_<-=N&SZEB,,\%C]+JW,OPOZ
M?B<U;*ZE&LL3A=?+_(_2*BORW^`GQT_;)_X)<6%OX7^,7PWU?X\?"_2QY-KX
MF\)3_P!IZOIENO0LA"S3QJO03(K`<>:P`%?;7[+7_!1CX-_MC)Y'@?QMIESK
MD8'VG0+XFPUFS;NLEG-ME&.Y"E?0FOGL3EU6DN>-IP_FCJOGV^9ZU'%PG[K]
MV79Z/_@_(X3_`(+9_#*_^+/_``2Y^+VFZ9#)<7MGI4>KI%&,LZV=Q%=2`#O^
M[A>O'_\`@VE^-NE_$7_@G-;^%[>>'^UO`&MWME>VX/SK'<3-=P2D?W765E![
MF)_2OT$O;*'4K*6WN(HY[>X1HY8I%#)(I&"I!X((."*_#;]I7]EKXQ_\$$/V
ML[_XO?!FRGU[X/:RY%S;&-Y[6SMF?<=/OU7YD2-B?)N1]T$`G.Y7]'+>7%82
M>`;M*_-&_5VLU]VQQXSFH5XXNUXVL_)=S[(_X*1?\$.)O^"EW[4;^-O$/Q)N
M?#&AZ5HMKI&D:=;Z8M^P97FDGE/F.JQAC(@PH).PDG@"OE/]I3_@U^\,_`3]
MGGQQXX@^+.J:E-X/T&]UE+27PW;QI=&W@>41LPERH;9C('&<X-?1GPA_X.@_
M@)XP\+03^+-'\<>#]6*@S6R:>-3M]W_3.:$Y8>[(A]JQ_P!KG_@X&_9Q^-/[
M*OQ)\(:+JWB]]9\4>&-1TJP67PY<1QM//;21QAF/"J689)Z#FN_#3SNBX45&
M2BK+X5:WK8YJ\<MJ*51M.3\V?!?PK_:)U[X0?\&^/CS1=)OKJV@\8?%,>&Y`
MCG%O8R:;%=W,2?W!+Y)5@.HE?U-?K+_P2/\`V,/A[^P?^PMX<\83VVDP^(==
M\.1>)O%'B:XC7S522W%PT8D/*6\,9VA5P/D+$$L37YU_\$W_`-B+4/V]/^"(
MWQ=\':'Y1\5:3X_&O:#'*X2.XO+?3[4>0S'A?-B>6,$\`NI/`-=7^QM_P6H\
M->"_V1-;_9I_:0TSQAX5O=(T:Y\&_P!M6NG//=6]FT36X@NK?_6Q3PQML5@K
M*P520#G=VYG1GB(U*.'W4[S2W::5GY_YG+@JD:4H5*W6/NM[7OL3_P#!8+_@
MH/\`L??M^_L]:PNA7&IR_%31E$WAO6!X9N+9KIE8;K:69D&ZWE3<,/PI*L,$
M<^+?M&?MR>,/%G_!!/X,^");ZYD_M?Q/J/AR_N6E;?>Z?I6V2WMY&SRN9K8'
M/46XSWKW;3_BO_P2ET^PAM_^$.O)_)C6/S)M*UUI),#&YCNY)[FO0?VNOV8_
MA!_P4_\`^"55M;?LF65A,OP?UB:\T_0+2TELKB1WC)N[5HY@)#-+'(LJ,Q/F
M,BC<<G%4JE"@J5.5*HH*=[S6BT:W];,4XU:O/-3BY.-K1Z[?H?<7_!.G]@_P
M5^PC^SKH.@>'=*L?[=N+*&?7M:\I3>:O=L@,CO)C=L#9")G:B@`#J3\C?\'(
M?[!W@WQI^R=J7QGT[2K+2/''@NYM?ME_:QB%]7LYIT@:.8KC>Z-*CHY^9=K`
M'#5QG_!/K_@X]\%>$?@UIG@KX\V7B30?&'A&!=*EU:VTV2ZBU$0C8&GB7]]!
M<`*`ZE""P)R,[1Y)_P`%,?\`@JAJO_!7[4]!_9Z_9Z\*Z_J.G:YJ,-S?75Y#
MY$^JF)MT8,8)\BSB;$LDLI!/EKPH!W>=A,!F%/,?;5;I)WE+I;KKYH[,1BL)
M/">SAK=62ZW/,_VI?$GB_P`*_##]D[]MS35EN?$L]O!HWB:Y&<ZAJ.ERRP12
MS-GDW=K!-$Y[[!ZU[W_P<*_MJC]J+P=\#OA#\-)7U?\`X6=%8^+S#"06NENL
M1:7`P'0M(\CL.QB0U]N_$3_@E[I>M_\`!(Y?V<8)HKN\T?PVD.G7[+@'5X3]
MH2Y&?NJ]UDG_`&)&%?F)_P`&Y?[(&H?'']MN]\=>*+6Z;3/@G:BWBAO,OY&J
MOYD,%N`W3R$%P^T?=;R^!FNW#XK#58/&/_EPY67=/X/NV1S5:%:$EAU_R]M?
MU7Q%CXJ?LB6?Q<_X*R_!/]D:^O)5^'WPGT&STZXCAD:(7[FR.JZG<+W66ZD(
M0L.0H&.E?NAX#^&7AWX7>![/PUX<T/2]$\/Z?`+:WTZRMDAMHH\8VA%&.G7U
M[U^4W_!<_P#9P^(/[*W[9'@[]L/X8V,FHQZ$+9/$:+&TJV4L`:))9U7YOLL]
MNY@D8?<VJ21N!'KWPY_X.<OV>?$GPXAU/Q!;>-?#FO"$-<:,FDM?$R8Y6&>,
M^4ZYZ,Y3W"UY^84L3C</1J8=.4;:I=)]6UYG7A*E'#5:D*WNN^E_Y>EO0^(/
M^#A[]B+PE^RO^UGX%\5>"M.M-"TOXEB2>]TNU01V]O?6T\(DEBC``195G0E1
MQN1B/O&OW3^+7PF\/?'?X7:WX.\5Z9;ZQX<\1V;V-_9S#*S1N,'W#`X*L.58
M`@@@&OYM/^"FW_!1+6/^"E'[2^C>,7T>ZT#P9H<JZ1X<LI3O,:":.2>260?(
M9W)C+JI(11&,G[S?O9_P4H_;]\/?\$[?V9]0\8ZG]GOM?NP;+PWHS2;7U:^*
M_*N!R(D^_(P^ZH_O,H.F;8;%>RPE&6M37UW5M?(C`5J'M*]1?!I^OYGX;_M-
M:C\5?^"+WQ;^,?P)\*>-O.\*>/-/C<SQ2A[C[%-GRYL*0;:\,(>"0X&Y"'`Q
MY;+^O_\`P1._X)SZ)^PC^RMI^H/)IFK>.?'UK;ZIK6JV<BS0")DWV]I;R#AH
M(E?[R\.[._0J!\!_\$_O^"-?B#_@IQ\%OB-\;OC%KVIVGBCXF":?PC>OE6^T
M;MW]I2Q][<E1#%%T\D,1C,;#H_\`@DC_`,%.[S_@FUX^\0_LS_M)W<GAC3_"
MUU)#HFHW8>:/1Y<[C:$J"6M9@PE@D`P-Y'W67;VYIS8G#RH8>2E4C;VB2UE9
M)77>S_K8YL%RT:L:M56A*_+?I_E<_:6J^KZO:Z!I=Q?7US;V5E9QM-/<7$@C
MB@11EG9B0%4`$DDX%<)X`_:)L?C):P77@[1]?U;3+A0Z:K>:?-I=BZG^)&N%
M220>\<;*?6NG\3_#S2_&]Q;-K-N-2AM666.SG.^U$@Y#F/[KL#R"X.T@$8/-
M?#N#C*T]#Z;FNKQ/DFZ_9GA_X*,?ML^'/B]XJT5XOA-\,=*O--\'V.HP%)O%
MUW=C;<:D\3`,EFL858`P#2L#+@)LWE?9;ZG;QWZ6K7$(NI%+K"7'F,HZD+UQ
M[T5T5,95E91;22LE?I_P^IE##P5VU=O<GHHHKD-PKSKXU?LB_"_]HU5/CGP#
MX5\33QX,5W>Z=&]W;D=#'/@2QD>JL#1150G*#YH.S%**DK25S#\-?LD/\+U*
M^"?B'\0=`M%4+%IM_J?]O6$0'\*K?"695]DF2MC4?'VL^#+P:7KQTG7Q,@1W
M@LVLPX(P=RM)*#[]!116\)NI+W]?S^_<RE%07NGG'CC_`(),?LT_&/4_[:UO
MX+>!GO[L"262ULOL>\GDEA`4#'W(K$_X<@?LI?\`1%?"_P#W]N?_`([115_7
M\5'2-25O5D_5:+U<%]R/5?V:/V(OA9^QRNJK\,O"-IX0BUQD>_AL[F<PW+("
M%=HW=EW`$C<!G'&<5#^T-^P7\&OVK[Z*\^(GPW\*>*;^%0B7UW9`7@4=%\]-
MLFT=ANQ116/UBKS^UYGS=[N_WFGL:?+R<JMVMH>8?\.0/V4O^B*^%_\`O[<_
M_':]/_9I_81^$W['5]JEQ\,O!MGX/?6U1;]+*YN#%=[,["\;R,A9=S8;&0"1
MG!HHJYXW$3CRSJ2:\VR8X:E%\T8I/T10^/O_``3E^!?[47B'^V/'GPN\(^(=
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M;ZDNA2>\5]Q[]H^CVGA[2+6PL+:"RL;&%+>VMX(Q'%!&@"JB*.%4```#@`5S
MVI?`OP5K/Q,A\:7?A'PU=>+[:!;6'6YM,A?4(HE)*HLY7>%!)P`>YHHK%2DM
M4S2R>C.JHHHJ1GPC^T?X";Q/^V[<>&H]3O++5==A^TV^KQG]Y8+Y32[0H(9B
A%B,0(D50DARC,`U%%%>U.O.$(*+^RNQYT:492DWW/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
